Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...

In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...

Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...

Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...